Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

DickMat schreef op 27 januari 2017 17:06:

De 0,33 gaat vandaag niet meer sneuvelen, wat inderdaad wel positief is dat er de afgelopen dagen veel handel boven de 0,30 is geweest. Zelf verwacht ik niet meer dat we hier onder gaan in de komende weken.

Prettig weekend

quote:

voda schreef op 27 januari 2017 16:47:

[...]
Zonder (dag) handelaren, was er niet, of amper handel geweest! Heb je daar wel eens je gedachten over laten gaan? :-)

quote:

lower schreef op 27 januari 2017 15:42:

[...]

Jij bent gek! Als je dat zo wil lezen.

Zeker kijk maar naar de overnamen en de omzetten van Dyax en Viropharma en Jerini.
Puur op omzet gekocht, LOL
Het gaat de grote Pharma om veelbelovende producten, zeldzame ziekte, het niet willen doen van R&D en toegang tot markten. Daarnaast verrekenbare verliezen

Kijk wat Pharming heeft betaald/gaat betalen aan Valeant, wat Valeant heeft afgeschreven: 200 mio dollar, de marktkapitalisatie nu en vooral ook de omzet die voor Pharming voor 2016 een 38-39 miljoen euro zal zijn!
Dat laatste lijkt me niet weinig voor een ontwikkelbedrijf...

Interessant artikel:
Why The 'Biotech Bubble' Is Economic Nonsense
seekingalpha.com/article/3582366-biot...
Daarnaast:
Pharming Group: A Potential Genzyme In The Making
www.pharming.com/pharming-group-a-pot...

Leuk artikel, paar maanden voor overname door Shire:
3 Reasons to Avoid Dyax Corp. Stock

Interested in Dyax? Here are three reasons to think about staying away.

Dyax Corp. (NASDAQ:DYAX) recently reported solid Q2 earnings, with encouraging updates on its major initiatives (particularly DX-2930, its big pipeline candidate -- more on that in a moment). The stock looks interesting, and it has a cool growth profile, given revenue streams from an expansive drug licensing portfolio. But there are three big reasons to bypass the stock. Let's dig in.

Concentrated value
When you look at Dyax's pipeline and listen to management's remarks, you notice that DX-2930, Dyax's drug for prevention of attacks of hereditary angioedema, or HAE, is the big value driver. And there's reason for management to be excited: In a phase 1b trial earlier this year, as DX-2930 showed statistically significant 100% and 88% reductions in HAE attacks in patient groups who received 300 mg and 400 mg doses of the drug, respectively.

While the data is exciting, it still only reflects a 37-patient phase 1b trial. Dyax will have to conduct a much larger phase 3 trial to better analyze the drug's safety and efficacy before submitting it for FDA approval. But the potential looks powerful. Analysts have previously estimated that DX-2930 could bring in $400 million or $500 million in peak sales, but those estimates were before management announced that it also plans to test the drug in diabetic macular edema.

Things look good... but the drug still has a way to go, and approval is far from guaranteed. Are you ready to bet your money on a company whose value is largely tied up in one drug that's only reported phase 1 data?

Moneymakers not that impressive so far
That's not to say that Dyax only has one drug. Far from it. In fact, the company has an 11-drug licensing and funded research portfolio, or LFRP, which it licenses out to a variety of partners, including big name such as Eli Lilly and Baxter. That portfolio brought in about $8.5 million last quarter from a combination of licensing fees and royalties on Lilly's Cyramza, the only drug from that portfolio that's been commercialized thus far. Dyax also has a marketed drug called Kalbitor, which treats HAE attacks and is expected to make between $60 million and $70 million in revenue this year.

All told, it's just not really that much. And while the drugs in the LFRP -- assuming they're successes in the clinic -- would probably bring in more money over time for Dyax, there's a potential big problem for Kalbitor.

Remember, if DX-2930 is approved, it could help prevent HAE attacks. Kalbitor helps treat HAE attacks. I see a potential trade-off there. Now, DX-2930 is expected to bring in a lot more money than Kalbitor, so it's still a win for the company if DX-2930 gets approved. But that's another problem the company would face as it struggles to turn the corner to profitability.

And look at that price!
Dyax isn't cheap, even by biotech's generally relaxed standards. Analysts polled by S&P Capital IQ estimate that Dyax will bring in almost $600 million in revenue in 2019. At today's roughly $3 billion market cap, that means the company is trading at around 5 times 2019 sales. That's expensive, particularly given that approval of DX-2930, which is a huge part of the company's value proposition, is by no means assured.

Let me be plain: I like Dyax as a company. But not at this price and with these other potential issues. I want to see phase 3 data from DX-2930 before being prepared to potentially buy. Of course, there's a problem with that: If the data look good, I'd be surprised if the stock didn't move higher -- thereby destroying the value proposition yet again for me. As for you, maybe you're less risk-averse than I am, or maybe you're willing to pay a little extra for the quality of the company's pipeline. There's a good argument for that kind of thinking in biotech. But Dyax isn't a company I'm going to change my investing philosophy for, so I'm happy sitting safely on the sidelines.

www.fool.com/investing/general/2015/0...

quote:

voda schreef op 27 januari 2017 16:47:

[...]
Zonder (dag) handelaren, was er niet, of amper handel geweest! Heb je daar wel eens je gedachten over laten gaan? :-)

quote:

Beur schreef op 27 januari 2017 16:30:

[...]Ik zal het bij standaard letters houden en mezelf er niet toe verlagen om eveneens met vetgedrukte letters hier net zo ongenuanceerd neer te kalken dat ik dit maar een arrogante en domme reactie vind. En nou niet echt uitnodigend tot een constructieve discussie.

In het kort: Beeldscherm citeerde hier iets dat betrekking had op de Amerikaanse markt en daarom refereerde ik mijn reactie op hem ook aan die markt. Met afstand de markt waar Pharming zijn centjes moet zien te verdienen. Dat hier al tig keer geplaatste Poolse onderzoek waar jij mee op de proppen komt heeft betrekking op de (Poolse) EU-markt.
Hoe we de waarde van rapporten van Roth moeten inschatten is inmiddels zelfs de meest fanatieke volgeling van De Vries inmiddels toch wel duidelijk, dacht ik.
En dat inmiddels overbekende staatje in dat rapport waar ook Pharming graag mee schermt en waarin vergelijkingen worden getrokken tussen de verschillende HAE-preparaten is afkomstig van Roth en NIET van een onafhankelijke bron.

quote:

lower schreef op 27 januari 2017 17:14:

[...]

Proppen we er gewoon een 2015 US onderzoek tegenaan, helaas nog zonder Ruconest
Tijd voor vervolg onderzoek om te laten zien dat Ruconest 'best in class' is

cdn.app.compendium.com/uploads/user/2...

Study: Drug Costs for Rare Hereditary Angioedema Disorder Tripled in Two Years
ST. PAUL, Minn., April 6, 2015 /PRNewswire/ -- Hereditary angioedema (HAE) – a rare genetic disorder that results in potentially life-threatening edema or swelling of limbs, abdomen, face, tongue or larynx – affects about 20 in 1 million Americans and still fewer commercially insured members. Yet individuals with the condition are accumulating specialty drug treatment costs of more than $300,000 annually on average, and according to a new study by pharmacy benefit manager Prime Therapeutics LLC (Prime), those costs tripled in the last two years. Researchers will present the study on April 9 at the Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting and Expo in San Diego, and recommend programs to help people with HAE and their health plans manage their condition to help improve care and reduce the growing cost of HAE care.

HAE drug treatments can address acute attacks or help prevent attacks in people who experience frequent episodes. But the specialty drugs carry a significant price tag, ranging from about $5,000 to more than $11,000 per dose (wholesale acquisition cost). Prime set out to understand the use of HAE medicines in order to identify opportunities to improve management of people with the condition.

Costs need to be evaluated on both medical and pharmacy benefits because some drugs are given by infusion in a medical facility, and others can be self-injected. Hence, Prime researchers reviewed integrated pharmacy and medical claims for 12.5 million members between January 2012 and March 2014. They identified members with claims for one of four specialty drugs prescribed for HAE: Berinert®, Cinryze®, Firazyr®, and Kalbitor®. A fifth treatment available today, Ruconest®, entered the market in September 2014, after the study was completed, so it was not included in this analysis.

During the two-year study, Prime identified 17 in 1 million commercially insured members as having a HAE diagnosis. Further analysis revealed 212 members had used a HAE drug, with more than $69 million in HAE drug costs, averaging $325,675 per member. Furthermore, 23 people out of 12.5 million commercially insured members had more than $1 million in HAE drug costs. In total, $45,385,602 (66%) of HAE drug costs were paid through the medical benefit and $23,657,387 (34%) were paid through the pharmacy benefit.

Prime also identified that quarterly HAE drug costs nearly tripled in two years. Per member per month (PMPM) cost of HAE drugs increased 191 percent, from $0.11 in the first quarter of 2012 to $0.32 PMPM in the first quarter of 2014. Higher costs were partially driven by the number of members taking these specialty drugs increasing substantially. In the first quarter of 2012, 45 members received a HAE drug, compared to 118 members in the first quarter of 2014, a 162 percent increase.

"Costs for HAE drugs are increasing at the same time the number of people being treated is increasing, and a subset of people incurred substantial treatment costs," said Patrick Gleason, PharmD, director of health outcomes at Prime. "This analysis demonstrates how essential integrated medical and pharmacy benefit claims reporting is to understanding HAE drug use and costs. With the integrated data, we have a clear picture of use and costs and can build care management programs to help our members and their health plans make the best use of these specialty drug treatments, prevent waste and improve care."

While a very small number of people use HAE drugs, the increased use and costs call for high touch case management as an essential HAE management tool. Careful case management of high cost members could potentially result in considerable savings through dosage adjustment and decreasing drug waste.

Prime deploys utilization management strategies such as aligning policies across both the medical and pharmacy benefits, following set criteria for medical review and pharmacy prior authorization to ensure the right people are receiving the most appropriate treatment. Care management nursing assessments are available with plans to expand in the future.

Visit primetherapeutics.com to read more about the study.

About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves more than 26 million people. It is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.

quote:

ruconestsucces schreef op 27 januari 2017 17:14:

[...]

en dan? is dat erg geen handel?volgende week mooi pers .

quote:

marlanki schreef op 27 januari 2017 17:19:

Ik verwacht volgende week of begin februari toch ook een persbericht van Pharming. Hoe en wanneer het eerste deel afbetaald gaat worden.
M.i.v. februari zouden die afbetalingen gaan starten volgens mij.

quote:

Beur schreef op 27 januari 2017 17:21:

[...]Je weet kennelijk niet dat een best in class product daarmee nog niet een succesvol produkt hoeft te zijn.
Heel veel hangt af van de snelheid waarmee men de concurrentie voor is. Zoals gezegd wanneer een patiënt eenmaal op medicatie zit die voor hem goed werkt, wordt er niet zo snel overgeschakeld op een ander medicijn. De arts is dan blij en de patiënt is blij. Een zeer bekend fenomeen.
Het zal heel wat effectieve promotie kosten om patiënten/artsen op andere gedachten te brengen. En zoals gezegd: het marketing-apparaat van een Shire of Berinert is natuurlijk veel krachtiger.

quote:

ruconestsucces schreef op 27 januari 2017 17:15:

je kunt ze volgende week beter wel hebben

quote:

lower schreef op 27 januari 2017 17:39:

Hoopmazzeln mag een Golden Raspberry in ontvangst nemen voor zijn posts in de categorie 'worst meeloper'
Een oeuvre award!
en.wikipedia.org/wiki/Golden_Raspberr...

Gefelicitaart!

Fijn weekend allen